Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Toshifumi Ozaki; Axel Hillmann; Christiane Hoffmann; Christian Rübe; Barbara Dockhorn-Dworniczak; Sebastian Blasius; Jürgen Dunst; Jörn Treuner; Herbert Jürgens; Winfried Winkelmann

doi:10.3109/17453679709003970

Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Toshifumi Ozaki^*, Axel Hillmann, Christiane Hoffmann, Christian Rübe, Barbara Dockhorn-Dworniczak, Sebastian Blasius, Jürgen Dunst, Jörn Treuner, Herbert Jürgens, Winfried Winkelmann

^*Corresponding author for this work

Department of Radiotherapy

University of Münster

15 Citations (Scopus)

Abstract

We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

Original language	English
Journal	Acta Orthopaedica Scandinavica
Volume	68
Issue number	1
Pages (from-to)	20-24
Number of pages	5
ISSN	0001-6470
DOIs	https://doi.org/10.3109/17453679709003970
Publication status	Published - 1997

Funding

The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant # M43/92/Jii2) and EC BIOMED 1’ (grant # BMHl -CT92-1341).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3109/17453679709003970

Cite this

@article{c6614a9a5ec140528e0e26470f016751,

title = "Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group",

abstract = "We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36\%, 65\%, and 65\% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.",

author = "Toshifumi Ozaki and Axel Hillmann and Christiane Hoffmann and Christian R{\"u}be and Barbara Dockhorn-Dworniczak and Sebastian Blasius and J{\"u}rgen Dunst and J{\"o}rn Treuner and Herbert J{\"u}rgens and Winfried Winkelmann",

note = "Funding Information: The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant \# M43/92/Jii2) and EC BIOMED 1{\textquoteright} (grant \# BMHl -CT92-1341). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "1997",

doi = "10.3109/17453679709003970",

language = "English",

volume = "68",

pages = "20--24",

journal = "Acta Orthopaedica Scandinavica",

issn = "0001-6470",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

AU - Ozaki, Toshifumi

AU - Hillmann, Axel

AU - Hoffmann, Christiane

AU - Rübe, Christian

AU - Dockhorn-Dworniczak, Barbara

AU - Blasius, Sebastian

AU - Dunst, Jürgen

AU - Treuner, Jörn

AU - Jürgens, Herbert

AU - Winkelmann, Winfried

N1 - Funding Information: The authors thank Mrs. S. Jabar for the statistical analysis and her help in preparing the manuscript. Funds were re- ceived in total or partial support of the research or clinical study presented in this article. The funding sources were the “Deutsche Krebshilfe” (grant # M43/92/Jii2) and EC BIOMED 1’ (grant # BMHl -CT92-1341). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 1997

Y1 - 1997

N2 - We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

AB - We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

UR - https://www.scopus.com/pages/publications/8044247185

U2 - 10.3109/17453679709003970

DO - 10.3109/17453679709003970

M3 - Journal articles

C2 - 9057563

AN - SCOPUS:8044247185

SN - 0001-6470

VL - 68

SP - 20

EP - 24

JO - Acta Orthopaedica Scandinavica

JF - Acta Orthopaedica Scandinavica

IS - 1

ER -

Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this